<VariationArchive VariationID="2422753" VariationName="NC_000022.10:g.(?_30070815)_(30077600_?)del" VariationType="Deletion" Accession="VCV002422753" Version="8" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1939067" VariationID="2422753">
      <GeneList>
        <Gene Symbol="NF2" FullName="NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor" GeneID="4771" HGNC_ID="HGNC:7773" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q12.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="29603556" stop="29698600" display_start="29603556" display_stop="29698600" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="29999544" stop="30094588" display_start="29999544" display_stop="30094588" Strand="+" />
          </Location>
          <OMIM>607379</OMIM>
          <Haploinsufficiency last_evaluated="2020-09-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=NF2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-09-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=NF2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000022.10:g.(?_30070815)_(30077600_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q12.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" innerStart="30070815" innerStop="30077600" display_start="30070815" display_stop="30077600" variantLength="6786" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.(?_30070815)_(30077600_?)del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.(?_30070815)_(30077600_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000022.10:g.(?_30070815)_(30077600_?)del AND Neurofibromatosis, type 2" Accession="RCV003109302" Version="4">
        <ClassifiedConditionList TraitSetID="840">
          <ClassifiedCondition DB="MedGen" ID="C0027832">Neurofibromatosis, type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-04-11" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-04-11" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19968670</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="840" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3089" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">NF 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neurofibromatosis central type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acoustic schwannomas bilateral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Bilateral acoustic neurofibromatosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acoustic neurinoma bilateral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neurofibromatosis type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Neurofibromatosis, type 2</ElementValue>
                <XRef ID="Neurofibromatosis+type+2/5175" DB="Genetic Alliance" />
                <XRef ID="92503002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SCHWANNOMATOSIS, VESTIBULAR</ElementValue>
                <XRef Type="MIM" ID="101000" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">BANF</ElementValue>
                <XRef Type="MIM" ID="101000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">SWNV</ElementValue>
                <XRef Type="MIM" ID="101000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ACN</ElementValue>
                <XRef Type="MIM" ID="101000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Neurofibromatosis 2 (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction. The average age of onset is 18 to 24 years. Almost all affected individuals develop bilateral vestibular schwannomas by age 30 years. Affected individuals may also develop schwannomas of other cranial and peripheral nerves, meningiomas, ependymomas, and, very rarely, astrocytomas. Because NF2 is considered an adult-onset disease, it may be underrecognized in children, in whom skin tumors and ocular findings (retinal hamartoma, thickened optic nerves, cortical wedge cataracts, third cranial nerve palsy) may be the first manifestations. Mononeuropathy that occurs in childhood is an increasingly recognized finding; it frequently presents as a persistent facial palsy or hand/foot drop.</Attribute>
                <XRef ID="NBK1201" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000552305" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528909" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569525" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522559" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528460" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552308" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552306" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000335548" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500116" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592488" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000593050" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514608" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528652" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000324942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000510681" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551659" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000576339" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000511190" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528930" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000335543" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521547" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522322" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7193" />
                <XRef ID="7193" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301380</ID>
                <ID Source="BookShelf">NBK1201</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2020">
                <ID Source="PubMed">32602153</ID>
              </Citation>
              <XRef ID="637" DB="Orphanet" />
              <XRef ID="C0027832" DB="MedGen" />
              <XRef ID="MONDO:0007039" DB="MONDO" />
              <XRef Type="MIM" ID="101000" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7071535" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_000268.3_22_Deletion (exons 13-15)|MedGen:C0027832" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003792010" DateUpdated="2024-06-09" DateCreated="2023-02-13" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19968670</ID>
          </Citation>
          <Comment>A similar copy number variant has been observed in individual(s) with Neurofibromatosis type 2 (PMID: 19968670). This variant is a gross deletion of the genomic region encompassing exon(s) 13-15 of the NF2 gene. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to disrupt the C-terminus of the protein. This variant disrupts a region of the NF2 protein in which other variant(s) (Deletion (Exons 14-15)) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="NF2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.(?_30070815)_(30077600_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027832" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7071535" TraitType="Disease" MappingType="XRef" MappingValue="C0027832" MappingRef="MedGen">
        <MedGen CUI="C0027832" Name="Neurofibromatosis, type 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

